Gespeichert in:
| Beteiligte Personen: | , , , , , |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | Englisch |
| Veröffentlicht: |
Washington, D.C
The World Bank
2007
|
| Schlagwörter: | |
| Links: | http://elibrary.worldbank.org/content/workingpaper/10.1596/1813-9450-4295 |
| Beschreibung: | Weitere Ausgabe: Adeyi, Olusoji : Economic benefit of Tuberculosis control |
| Umfang: | 1 Online-Ressource (59 Seiten) |
Internformat
MARC
| LEADER | 00000nam a2200000 c 4500 | ||
|---|---|---|---|
| 001 | BV040618899 | ||
| 003 | DE-604 | ||
| 005 | 20250120 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 121206s2007 xxu o|||| 00||| eng d | ||
| 035 | |a (ZDB-1-WBA)093228465 | ||
| 035 | |a (OCoLC)837708304 | ||
| 035 | |a (DE-599)GBVNLM005464617 | ||
| 040 | |a DE-604 |b ger |e aacr | ||
| 041 | 0 | |a eng | |
| 044 | |a xxu |c XD-US | ||
| 049 | |a DE-12 |a DE-1102 |a DE-1051 |a DE-521 |a DE-863 |a DE-862 |a DE-522 |a DE-858 |a DE-573 |a DE-860 |a DE-1046 |a DE-1047 |a DE-Aug4 |a DE-2070s |a DE-M347 |a DE-1049 |a DE-898 |a DE-128 |a DE-M352 |a DE-70 |a DE-92 |a DE-150 |a DE-155 |a DE-22 |a DE-91 |a DE-384 |a DE-473 |a DE-19 |a DE-739 |a DE-20 |a DE-703 |a DE-706 |a DE-355 |a DE-29 |a DE-859 |a DE-Re13 |a DE-523 | ||
| 100 | 1 | |a Adeyi, Olusoji |e Verfasser |4 aut | |
| 245 | 1 | 0 | |a Economic benefit of Tuberculosis control |c Adeyi, Olusoji |
| 264 | 1 | |a Washington, D.C |b The World Bank |c 2007 | |
| 300 | |a 1 Online-Ressource (59 Seiten) | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 500 | |a Weitere Ausgabe: Adeyi, Olusoji : Economic benefit of Tuberculosis control | ||
| 520 | 1 | |a Tuberculosis is the most important infectious cause of adult deaths after HIV/AIDS in low- and middle-income countries. This paper evaluates the economic benefits of extending the World Health Organization's DOTS Strategy (a multi-component approach that includes directly observed treatment, short course chemotherapy and several other components) as proposed in the Global Plan to Stop TB, 2006-2015. The authors use a model-based approach that combines epidemiological projections of averted mortality and economic benefits measured using value of statistical life for the Sub-Saharan Africa region and the 22 high-burden, tuberculosis-endemic countries in the world. The analysis finds that the economic benefits between 2006 and 2015 of sustaining DOTS at current levels relative to having no DOTS coverage are significantly greater than the costs in the 22 high-burden, tuberculosis-endemic countries and the Africa region. The marginal benefits of implementing the Global Plan to Stop TB relative to a no-DOTS scenario exceed the marginal costs by a factor of 15 in the 22 high-burden endemic countries, a factor of 9 (95% CI, 8-9) in the Africa region, and a factor of 9 (95% CI, 9-10) in the nine high-burden African countries. Uncertainty analysis shows that benefit-cost ratios of the Global Plan strategy relative to sustained DOTS were unambiguously greater than one in all nine high-burden countries in Africa and in Afghanistan, Pakistan, and Russia. Although HIV curtails the effect of the tuberculosis programs by lowering the life expectancy of those receiving treatment, the benefits of the Global Plan are greatest in African countries with high levels of HIV | |
| 534 | |c 2007 | ||
| 653 | |a Aged | ||
| 653 | |a Chemotherapy | ||
| 653 | |a Disease Control and Prevention | ||
| 653 | |a Families | ||
| 653 | |a Health Monitoring and Evaluation | ||
| 653 | |a Health Systems Development and Reform | ||
| 653 | |a Health, Nutrition and Population | ||
| 653 | |a Life expectancy | ||
| 653 | |a Morbidity | ||
| 653 | |a Mortality | ||
| 653 | |a Nutrition | ||
| 653 | |a Patients | ||
| 653 | |a Population Policies | ||
| 653 | |a Public health | ||
| 653 | |a Unemployment | ||
| 700 | 1 | |a Dye, Christopher |e Verfasser |4 aut | |
| 700 | 1 | |a Klein, Eili |e Verfasser |4 aut | |
| 700 | 1 | |a Floyd, Katherine |e Verfasser |4 aut | |
| 700 | 1 | |a Laxminarayan, Ramanan |e Verfasser |0 (DE-588)17189264X |4 aut | |
| 700 | 1 | |a Darley, Sarah |e Verfasser |4 aut | |
| 776 | 0 | 8 | |i Reproduktion von |a Adeyi, Olusoji |t Economic benefit of Tuberculosis control |d 2007 |
| 856 | 4 | 0 | |u http://elibrary.worldbank.org/content/workingpaper/10.1596/1813-9450-4295 |x Verlag |z URL des Erstveröffentlichers |3 Volltext |
| 912 | |a ZDB-1-WBA | ||
| 943 | 1 | |a oai:aleph.bib-bvb.de:BVB01-025446398 | |
Datensatz im Suchindex
| DE-BY-OTHR_katkey | 5052141 |
|---|---|
| DE-BY-TUM_katkey | 1901315 |
| DE-BY-UBR_katkey | 5052141 |
| _version_ | 1835105090930737152 |
| adam_text | |
| any_adam_object | |
| author | Adeyi, Olusoji Dye, Christopher Klein, Eili Floyd, Katherine Laxminarayan, Ramanan Darley, Sarah |
| author_GND | (DE-588)17189264X |
| author_facet | Adeyi, Olusoji Dye, Christopher Klein, Eili Floyd, Katherine Laxminarayan, Ramanan Darley, Sarah |
| author_role | aut aut aut aut aut aut |
| author_sort | Adeyi, Olusoji |
| author_variant | o a oa c d cd e k ek k f kf r l rl s d sd |
| building | Verbundindex |
| bvnumber | BV040618899 |
| collection | ZDB-1-WBA |
| ctrlnum | (ZDB-1-WBA)093228465 (OCoLC)837708304 (DE-599)GBVNLM005464617 |
| discipline | Wirtschaftswissenschaften |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>00000nam a2200000 c 4500</leader><controlfield tag="001">BV040618899</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20250120</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">121206s2007 xxu o|||| 00||| eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-1-WBA)093228465</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)837708304</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)GBVNLM005464617</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">aacr</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="044" ind1=" " ind2=" "><subfield code="a">xxu</subfield><subfield code="c">XD-US</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-12</subfield><subfield code="a">DE-1102</subfield><subfield code="a">DE-1051</subfield><subfield code="a">DE-521</subfield><subfield code="a">DE-863</subfield><subfield code="a">DE-862</subfield><subfield code="a">DE-522</subfield><subfield code="a">DE-858</subfield><subfield code="a">DE-573</subfield><subfield code="a">DE-860</subfield><subfield code="a">DE-1046</subfield><subfield code="a">DE-1047</subfield><subfield code="a">DE-Aug4</subfield><subfield code="a">DE-2070s</subfield><subfield code="a">DE-M347</subfield><subfield code="a">DE-1049</subfield><subfield code="a">DE-898</subfield><subfield code="a">DE-128</subfield><subfield code="a">DE-M352</subfield><subfield code="a">DE-70</subfield><subfield code="a">DE-92</subfield><subfield code="a">DE-150</subfield><subfield code="a">DE-155</subfield><subfield code="a">DE-22</subfield><subfield code="a">DE-91</subfield><subfield code="a">DE-384</subfield><subfield code="a">DE-473</subfield><subfield code="a">DE-19</subfield><subfield code="a">DE-739</subfield><subfield code="a">DE-20</subfield><subfield code="a">DE-703</subfield><subfield code="a">DE-706</subfield><subfield code="a">DE-355</subfield><subfield code="a">DE-29</subfield><subfield code="a">DE-859</subfield><subfield code="a">DE-Re13</subfield><subfield code="a">DE-523</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Adeyi, Olusoji</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Economic benefit of Tuberculosis control</subfield><subfield code="c">Adeyi, Olusoji</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Washington, D.C</subfield><subfield code="b">The World Bank</subfield><subfield code="c">2007</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (59 Seiten)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Weitere Ausgabe: Adeyi, Olusoji : Economic benefit of Tuberculosis control</subfield></datafield><datafield tag="520" ind1="1" ind2=" "><subfield code="a">Tuberculosis is the most important infectious cause of adult deaths after HIV/AIDS in low- and middle-income countries. This paper evaluates the economic benefits of extending the World Health Organization's DOTS Strategy (a multi-component approach that includes directly observed treatment, short course chemotherapy and several other components) as proposed in the Global Plan to Stop TB, 2006-2015. The authors use a model-based approach that combines epidemiological projections of averted mortality and economic benefits measured using value of statistical life for the Sub-Saharan Africa region and the 22 high-burden, tuberculosis-endemic countries in the world. The analysis finds that the economic benefits between 2006 and 2015 of sustaining DOTS at current levels relative to having no DOTS coverage are significantly greater than the costs in the 22 high-burden, tuberculosis-endemic countries and the Africa region. The marginal benefits of implementing the Global Plan to Stop TB relative to a no-DOTS scenario exceed the marginal costs by a factor of 15 in the 22 high-burden endemic countries, a factor of 9 (95% CI, 8-9) in the Africa region, and a factor of 9 (95% CI, 9-10) in the nine high-burden African countries. Uncertainty analysis shows that benefit-cost ratios of the Global Plan strategy relative to sustained DOTS were unambiguously greater than one in all nine high-burden countries in Africa and in Afghanistan, Pakistan, and Russia. Although HIV curtails the effect of the tuberculosis programs by lowering the life expectancy of those receiving treatment, the benefits of the Global Plan are greatest in African countries with high levels of HIV</subfield></datafield><datafield tag="534" ind1=" " ind2=" "><subfield code="c">2007</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Aged</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Chemotherapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Disease Control and Prevention</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Families</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Health Monitoring and Evaluation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Health Systems Development and Reform</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Health, Nutrition and Population</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Life expectancy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Morbidity</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Mortality</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Nutrition</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Patients</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Population Policies</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Public health</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Unemployment</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Dye, Christopher</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Klein, Eili</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Floyd, Katherine</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Laxminarayan, Ramanan</subfield><subfield code="e">Verfasser</subfield><subfield code="0">(DE-588)17189264X</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Darley, Sarah</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Reproduktion von</subfield><subfield code="a">Adeyi, Olusoji</subfield><subfield code="t">Economic benefit of Tuberculosis control</subfield><subfield code="d">2007</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://elibrary.worldbank.org/content/workingpaper/10.1596/1813-9450-4295</subfield><subfield code="x">Verlag</subfield><subfield code="z">URL des Erstveröffentlichers</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-WBA</subfield></datafield><datafield tag="943" ind1="1" ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-025446398</subfield></datafield></record></collection> |
| id | DE-604.BV040618899 |
| illustrated | Not Illustrated |
| indexdate | 2025-01-20T11:02:28Z |
| institution | BVB |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-025446398 |
| oclc_num | 837708304 |
| open_access_boolean | |
| owner | DE-12 DE-1102 DE-1051 DE-521 DE-863 DE-BY-FWS DE-862 DE-BY-FWS DE-522 DE-858 DE-573 DE-860 DE-1046 DE-1047 DE-Aug4 DE-2070s DE-M347 DE-1049 DE-898 DE-BY-UBR DE-128 DE-M352 DE-70 DE-92 DE-150 DE-155 DE-BY-UBR DE-22 DE-BY-UBG DE-91 DE-BY-TUM DE-384 DE-473 DE-BY-UBG DE-19 DE-BY-UBM DE-739 DE-20 DE-703 DE-706 DE-355 DE-BY-UBR DE-29 DE-859 DE-Re13 DE-BY-UBR DE-523 |
| owner_facet | DE-12 DE-1102 DE-1051 DE-521 DE-863 DE-BY-FWS DE-862 DE-BY-FWS DE-522 DE-858 DE-573 DE-860 DE-1046 DE-1047 DE-Aug4 DE-2070s DE-M347 DE-1049 DE-898 DE-BY-UBR DE-128 DE-M352 DE-70 DE-92 DE-150 DE-155 DE-BY-UBR DE-22 DE-BY-UBG DE-91 DE-BY-TUM DE-384 DE-473 DE-BY-UBG DE-19 DE-BY-UBM DE-739 DE-20 DE-703 DE-706 DE-355 DE-BY-UBR DE-29 DE-859 DE-Re13 DE-BY-UBR DE-523 |
| physical | 1 Online-Ressource (59 Seiten) |
| psigel | ZDB-1-WBA |
| publishDate | 2007 |
| publishDateSearch | 2007 |
| publishDateSort | 2007 |
| publisher | The World Bank |
| record_format | marc |
| spellingShingle | Adeyi, Olusoji Dye, Christopher Klein, Eili Floyd, Katherine Laxminarayan, Ramanan Darley, Sarah Economic benefit of Tuberculosis control |
| title | Economic benefit of Tuberculosis control |
| title_auth | Economic benefit of Tuberculosis control |
| title_exact_search | Economic benefit of Tuberculosis control |
| title_full | Economic benefit of Tuberculosis control Adeyi, Olusoji |
| title_fullStr | Economic benefit of Tuberculosis control Adeyi, Olusoji |
| title_full_unstemmed | Economic benefit of Tuberculosis control Adeyi, Olusoji |
| title_short | Economic benefit of Tuberculosis control |
| title_sort | economic benefit of tuberculosis control |
| url | http://elibrary.worldbank.org/content/workingpaper/10.1596/1813-9450-4295 |
| work_keys_str_mv | AT adeyiolusoji economicbenefitoftuberculosiscontrol AT dyechristopher economicbenefitoftuberculosiscontrol AT kleineili economicbenefitoftuberculosiscontrol AT floydkatherine economicbenefitoftuberculosiscontrol AT laxminarayanramanan economicbenefitoftuberculosiscontrol AT darleysarah economicbenefitoftuberculosiscontrol |